ID 1391 Cutaneous T-cell lymphoma relapsed vorinostat |
Insufficient evidence/superior alternatives |
07/03/2014 |
ID 1670 Lymphoma EPOCH (etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXOrubicin) |
Superior alternatives available |
28/10/2014 |
ID 632 Non-Hodgkin lymphoma R-CHOEP21 (RITUXimab CYCLOPHOSphamide DOXOrubicin VinCRIStine ETOPOside prednisolone) |
Insufficient evidence |
28/10/2014 |
ID 912 Non-Hodgkin lymphoma R-CNOP ( RITUximab CYCLOPHOSPHamide mitozantrone vinCRISTine prednisolone ) |
Insufficient evidence/no clinical need |
28/10/2014 |
ID 1136 Non-Hodgkin lymphoma FGIV ( gemcitabine IFOSFamide vinORELBine ) |
Superior alternatives available |
19/10/2016 |
ID 663 Non-Hodgkin lymphoma FM ( fludarabine mitozantrone ) |
Insufficient demand |
16/10/2016 |
ID 666 Non-Hodgkin lymphoma FCM ( Fludarabine CYCLOPHOSPHamide mitozantrone ) |
Insufficient demand |
16/10/2016 |
ID 372 Hodgkin lymphoma mini-BEAM (carmustine, cytarabine, etoposide, melphalan) |
Insufficient demand |
16/10/2016 |
ID 626 Hodgkin lymphoma mini-dexa BEAM (dexamethasone, carmustine, cytarabine, etoposide, melphalan) |
Insufficient demand |
16/10/2016 |
ID 687 Non-Hodgkin lymphoma chlorambucil prednisolone |
Superior alternatives available |
16/10/2016 |
ID 1546 Non-Hodgkin lymphoma bendamustine |
Superior alternatives available |
16/10/2016 |
ID TBC Hodgkin lymphoma bendamustine and brentuximab vedotin |
Indication/combination not approved by TGA |
07/09/2022 |
ID TBC Hodgkin lymphoma Pembro-GVD (pembrolizumab gemcitabine vinorelbine liposomal doxorubicin) |
Indication/combination not approved by TGA |
21/02/2023 |
ID TBC Hodgkin lymphoma BrECADD (brentuximab vedotin, etoposide, doxorubicin, cyclophosphamide, dacarbazine, dexamethasone) |
Combination not approved by TGA |
08/07/2024 |